Novel immunotherapy demonstrates Long-Lasting benefits HRP Ovarian Cancer

A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.

Share on Facebook

Tweet

Follow us

Save